文献速递临床试验与 GCP流行病学与生物统计

镰状细胞病孕妇序贯预防性交换输血(TAPS-2):随机对照可行性试验研究方案

Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial.
PubMed 文献 · Trials · 2020-04-20

主要结局为招募率,并嵌入定性研究和卫生经济学研究,为未来三期随机对照试验提供依据。

要点

  • SPEBT从孕≤18周开始,每6-10周进行自动化红细胞置换,目标维持HbS%或HbS/HbC%低于30%。
  • 标准 care 组仅在临床需要时输血。
  • 主要结局为招募率,次要包括拒绝原因、脱落率、方案依从性及母婴结局。

核心结论

  • 本研究旨在严格评估SPEBT作为妊娠期镰状细胞病治疗方案的可行性及其对母婴结局的影响。

研究设计与样本

  • 个体随机、两臂可行性试验,嵌入定性研究和卫生经济学研究。
  • 随机化通过安全在线数据库进行,按中心、镰状细胞病基因型和母亲年龄最小化。

关键数值与推荐

  • 干预组从孕≤18周开始接受SPEBT,使用自动化红细胞置换术,每6-10周一次直至妊娠结束,目标维持HbS%或联合HbS/HbC%低于30%。
  • 标准 care 组仅在临床有指征时输血。
  • 主要结局为招募率;附加终点包括拒绝参与原因、脱落率、方案依从性及母婴结局。

临床怎么用

  • 目前证据尚不足以支持SPEBT在妊娠期镰状细胞病中的常规应用,需等待本可行性试验及未来三期试验结果。

局限性

  • 研究仅在英格兰六家医院开展,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancies in women with sickle cell disease (SCD) are associated with a higher risk of sickle and pregnancy complications. Limited options exist for treating SCD during pregnancy. Serial prophylactic exchange blood transfusion (SPEBT) has been shown to be effective in treating SCD outside pregnancy, but evidence is lacking regarding its use during pregnancy. The aim of this study is to assess the feasibility and acceptability of conducting a future phase 3 randomised controlled trial (RCT) to establish the clinical and cost effectiveness of SPEBT in pregnant women with SCD. METHODS: The study is an individually randomised, two-arm, feasibility trial with embedded qualitative and health economic studies. Fifty women, 18 years of age and older, with SCD and a singleton pregnancy at ≤ 18 weeks' gestation will be recruited from six hospitals in England. Randomisation will be conducted using a secure online database and minimised by centre, SCD genotype and maternal age. Women allocated to the intervention arm will receive SPEBT commencing at ≤ 18 weeks' gestation, performed using automated erythrocytapheresis every 6-10 weeks until the end of pregnancy, aiming to maintain HbS% or combined HbS/HbC% below 30%. Women in the standard care arm will only receive transfusion when clinically indicated. The primary outcome will be the recruitment rate. Additional endpoints include reasons for refusal to participate, attrition rate, protocol adherence, and maternal and neonatal outcomes. Women will be monitored throughout pregnancy to assess maternal, sickle, and foetal complications. Detailed information about adverse events (including hospital admission) and birth outcomes will be extracted from medical records and via interview at 6 weeks postpartum. An embedded qualitative study will consist of interviews with (a) 15-25 trial participants to assess experiences and acceptability, (b) 5-15 women who decline to participate to identify barriers to recruitment and (c) 15-20 clinical staff to explore fidelity and acceptability. A health economic study will inform a future cost effectiveness and cost-utility analysis. DISCUSSION: This feasibility study aims to rigorously evaluate SPEBT as a treatment for SCD in pregnancy and its impact on maternal and infant outcomes. TRIAL REGISTRATION: NIH registry (www.clinicaltrials.gov), registration number NCT03975894 (registered 05/06/19); ISRCTN (www.isrctn.com), registration number ISRCTN52684446 (retrospectively registered 02/08/19).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Oakley LL, Awogbade M, Brien S, et al. Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial. Trials. 2020. PMID: 32312326. doi:10.1186/s13063-020-4212-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。